Abstract: New antibacterial treatments against Helicobacter pylori are needed as H. pylori is acquiring\nantibiotic resistance. Beta-caryophyllene is a natural bicyclic sesquiterpene, with anti-inflammatory\nand antimicrobial effects. This study investigates the effects of H-002119-00-001 from Beta-caryophyllene on the eradication of H. pylori in a mouse model, and its effects on the inflammation\nof the gastric mucosa. To evaluate the anti-H.pylori efficacy of beta -caryophyllene, a total of 160 mice\nwere divided into eight groups (n = 10 each) and were administered different treatments for 2 and\n4 weeks. H. pylori eradication was assessed using a Campylobacter-like organism (CLO) test and H.\npylori qPCR of the gastric mucosa. The levels of inflammation of gastric mucosa were assessed using\nhistology and immunostaining. H-002119-00-001 decreased bacterial burden in vitro. When H-\n002119-00-001 was administered to mice once daily for 2 weeks, cure rates shown by the CLO test\nwere 40.0%, 60.0%, and 70.0% in groups 6, 7, and 8, respectively. H. pylori levels in gastric mucosa\ndecreased dose-dependently after H-002119-00-001 treatment. H-002119-00-001 also reduced levels\nof inflammation in gastric mucosa. H-002119-00-001 improved inflammation and decreased\nbacterial burden in H. pylori-infected mouse models. H-002119-00-001 is a promising and effective\ntherapeutic agent for the treatment of H. pylori infection.
Loading....